±MÃD°Q½×18¡G¥\¯à©Ê¸£³¡¯fÅܪvÀø¤§·s¶i®i
Advances in the Treatment for the Functional Brain Diseases

S18-1
°ò¦]¬ã¨s¹ï©ó¤Úª÷´Ë¯f¶EÂ_¤ÎªvÀø¤§½ÄÀ»
Implication of Gentics on the Diagnosis and Treatment of Patients with Parkinson¡¦s Disease
ªLÀR¼_ ³¯©s§D* À¹¬K·u* §d·ç¬ü*
¥x¤jÂå°|¶³ªL¤À°|¯«¸g³¡ ¥x¤jÂå°|¯«¸g³¡*

¡@¡@¤Úª÷´Ë¯f(¤Ú¯f)¬O°£¤Fªü¯÷®üÀq¥¢´¼¯g¤§¥~³Ì´¶¹Mªº¯«¸g°h¤Æ©Ê¯e¯f¡A¬ù¦û65·³¥H¤W¦Ñ¦~¤H¤fªº1-2%¡A¨ä¤¤5-10%ªº¯f¤H¨ã¦³®a±Ú¿ò¶Ç¥v¡]Åã©Ê»PÁô©Ê¿ò¶Ç¼Ò¦¡¬Ò¦³¡^¡A®Ú¾Ú²Î­p¡Aµo¥Í²v¦³ÀHµÛ¦~ÄÖ¼W¥[¦Ó´£°ªªº²{¶H(¤»¤Q·³¥H¤Wªº¬y¦æ²v¬°1 %¡A¤C¤Q¦Ü¤K¤Q·³«h¬ù¬°1.5%)¡A¦ý¬O¦³¤Ö¼Æ¯f¤Hªºµo¯f¦~ÄÖ·|´£¦­¨ì50·³¤§«eµo¯f¡A³oÃþ¯f¤HºÙ¤§¬°¦~»´«¬ªº¤Ú¯f±wªÌ¡A¬ù¦û©Ò¦³¤Ú¯f±wªÌªº4-12%¡C

¡@¡@¤Ú¯fªº¯f¦]¹L¥h¤@ª½»{¬°©MÀô¹Ò¦]¯À¦³¬Û·í¤jªºÃö«Y¡A¥]¬A¹AÃÄ(¦³¾÷ÁCÃþ)¥H¤Î­«ª÷Äݦp¿øµ¥¡AµM¦Ó¡A³Ìªñ´X¦~ªº¬ã¨sµo²{¬Y¨Ç°ò¦]ªº¬ðÅÜ·|¾É­P¿ò¶Ç©Ê¤Ú¯fªºµo¥Í¡A¥Ø«e¤w¦³11­Ó°ò¦]ªº¬ðÅܤw³QÃÒ¹ê¬O¤Þ°_¤Ö¼Æ¿ò¶Ç©Ê¤Ú¯fªº­P¯f¦]¡A¥]¬AƒÑ-synuclein¡BUCHL-1¡BParkin¡BDJ-1¡BPINK1¡BLRRK2¡BATP13A2¡BHtrA2¡B Fbxo7¡BGIGYF2»PPLA2G6¡F®Ú¾Ú§Ú­Ì¹L¥hªº¬ã¨s¡Aµo²{LRRK2°ò¦]¤WªºG2385R»PR1628P¬°¨È¬w¤HºØ¤¤¿W¯Sªº¤Ú¯f¯e¯f¦MÀI¦]¤l¡A§Ú­Ìµo²{¡A­Y¬O±a¦³³o¨Ç°ò¦]¦MÀI¦]¤l¡A±N·|¨Ï±o¨ì¤Ú¯fªº¦MÀI©Ê¼W¥[2­¿¤§°ª¡C°£¤F¿ò¶Ç¦]¯À¤§¥~¡A¤Ú¯fªº¯f¦]¹L¥h¤@ª½»{¬°¤]©MÀô¹Ò¦]¯À¦³¬Û·í¤jªºÃö«Y¡A¥]¬A¹AÃÄ(¦³¾÷ÁCÃþorganophospate group)¥H¤Î­«ª÷Äݦp¿ø (Mn)µ¥ªº¼ÉÅS¡A¤]·|¼W¥[¿©±w¤Ú¯fªº¦MÀI©Ê¡C¥i±¤ªº¬O¡A¥Ø«e¤åÄm¤W¶È¦³¤Ö¼Æªº¬ã¨s±´°Q°ò¦]»PÀô¹Òªº¥æ¤¬§@¥Î¹ï¤Ú¯f¿©¯f¦MÀI©Êªº¼vÅT¡C¦]¦¹¡A®Ú¾Ú§Ú­Ìªñ¤é¤j³W¼Òªº°ò¦]¦h«¬©Ê»P½w¹Ò¦]¤lªº¥æ¤¬¬ã¨s¤¤¡A§Ú­Ìµo²{¡A­Y¦P®É¥[¤JÀô¹Ò¦MÀI¦]¤l¼ÉÅSªº¤ÀªR¡ALRRK2 T4939A (S1647T)·|¤j¤j¼W¥[¤Ú¯fªº¿©¯f¾÷²v(TT, OR = -0.36, p = 0.03)¡A¥t¥~¡A§Ú­Ì¤]µo²{¹AÃĪº¼ÉÅS·|»PBDNF (OR = -0.85, p = 0.01) ¥H¤ÎPINK1 (OR = 1.99, p = 0.07)µ¥°ò¦]Åܲ§¦³ÅãµÛªº¥æ¤¬§@¥Î¡A¶i¦Ó¼vÅT¿©¯fªº¦MÀI©Ê¡C

¡@¡@ºî¤W¦Ó½×¡A°ò¦]«¬¤Úª÷´Ë¯f¥i°µ¬°°¸µo«¬¤Úª÷´Ë¯fªº¬ã¨s¼Ò¦¡¡A¦³§U©ó¤F¸Ñ­P¯f¾÷Âà¤Î·sÃĵo®i¡A¨Ò¦p¦bÁô©Ê¿ò¶Çªº¤Úª÷´Ë¤ó¯f¡A°ò¦]²§±`³y¦¨³J¥Õ½è¥\¯à³à¥¢¡AÅã©Ê¿ò¶Ç«h¬°³y¦¨¦³¬rªº³J¥ÕÅé²Ö¿n¡A«eªÌ¬O­n¼W¥[¯S©w³J¥Õ½èªº¥\¯à¡A«áªÌ«h¬°·»¸Ñ©Î²¾°£²§±`³J¥Õ¤§²Ö¿n¡C¬Û«H¦b«á°ò¦]®É¥N¡AŲ©w¥X©ö·P©Ê°ò¦]¦]¤l¡A¸g¥Ñ¤À¤l²Ó­M¾Ç¤Î°Êª«¼Ò¦¡¡Aµo©ú·sªºªvÀøÃĪ«¡A¥H§ã¤î¤Úª÷´Ë¯f¤§´c¤Æ¡A¦P®É¹w¨¾¯e¯f¤§²£¥Í¡C